A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Pre-Pen
Synonyms :
Benzylpenicilloyl G polylysine,
Class :
Diagnostic agent, Allergen immunotherapy
Brand Name :
Pre-Pen
Synonyms :
Benzylpenicilloyl G polylysine,
Class :
Diagnostic agent, Allergen immunotherapy
Dosage Forms & Strengths
Injectable solutions
Safety and efficacy data are not available
Refer to adult dosing
may decrease the diagnostic effect when combined with benzylpenicilloyl polylysine
bunazosin (Not available in the United States)
may decrease the diagnostic effect when combined with benzylpenicilloyl polylysine
may decrease the diagnostic effect when combined with benzylpenicilloyl polylysine
may decrease the diagnostic effect when combined with benzylpenicilloyl polylysine
may decrease the diagnostic effect when combined with benzylpenicilloyl polylysine
It may decrease the diagnostic effect when combined with Alpha-/Beta-Agonists
It may decrease the diagnostic effect when combined with Alpha-/Beta-Agonists
It may decrease the diagnostic effect when combined with Alpha-/Beta-Agonists
It may decrease the diagnostic effect when combined with Alpha-/Beta-Agonists
It may decrease the diagnostic effect when combined with Alpha-/Beta-Agonists
dexchlorpheniramine, dextromethorphan, and phenylephrine
benzylpenicilloyl polylysine: they may decrease the diagnostic effect of antihistamines
benzylpenicilloyl polylysine: they may decrease the diagnostic effect of antihistamines
benzylpenicilloyl polylysine: they may decrease the diagnostic effect of antihistamines
benzylpenicilloyl polylysine: they may decrease the diagnostic effect of antihistamines
benzylpenicilloyl polylysine: they may decrease the diagnostic effect of antihistamines
acrivastine and pseudoephedrine
may decrease the diagnostic effect of antihistamines
may decrease the diagnostic effect of antihistamines
may decrease the diagnostic effect of antihistamines
acetaminophen/doxylamine/dextromethorphan
may decrease the diagnostic effect of Antihistamines
the anticoagulant effects of acenocoumarol may be increased with benzylpenicilloyl polylysine
the anticoagulant effects of acrivastine may be increased with benzylpenicilloyl polylysine
triamcinolone acetonide/nystatin
It may enhance the risk of adverse effects when combined with diagnostic agents
It may enhance the risk of adverse effects when combined with diagnostic agents
methenamine/sodium salicylate/benzoic acid
It may enhance the risk of adverse effects when combined with diagnostic agents
It may enhance the risk of adverse effects when combined with diagnostic agents
It may enhance the risk of adverse effects when combined with diagnostic agents
the rate of excretion of benzylpenicilloyl polylysine may be reduced with acemetacin
the risk of methemoglobinemia may be increased when benzylpenicillolyl polylysine is taken with ambroxol
the efficacy of benzylpenicillolyl polylysine as a diagnostic agent may be decreased with amitriptyline
the efficacy of benzylpenicillolyl polylysine as a diagnostic agent may be decreased with benztropine
the efficacy of benzylpenicillolyl polylysine as a diagnostic agent may be decreased with bethanidine
the efficacy of benzylpenicillolyl polylysine as a diagnostic agent may be decreased with bilastine
the efficacy of benzylpenicillolyl polylysine as a diagnostic agent may be decreased with cinnarizine
the efficacy of benzylpenicillolyl polylysine as a diagnostic agent may be decreased with cimetidine
the serum levels of colistin may be reduced when taken with benzylpenicillolyl polylysine
the therapeutic activity of desogestrel may be reduced when combined with benzylpenicillolyl polylysine
the efficacy of benzylpenicillolyl polylysine as a diagnostic agent may be decreased with dimenhydrinate
the efficacy of benzylpenicillolyl polylysine as a diagnostic agent may be decreased with diphenhydramine
the efficacy of benzylpenicillolyl polylysine as a diagnostic agent may be decreased with epinephrine
the therapeutic activity of estradiol may be reduced when combined with benzylpenicillolyl polylysine
the therapeutic activity of etilefrine may be reduced when combined with benzylpenicillolyl polylysine
the serum levels of framycetin may be reduced when taken with benzylpenicillolyl polylysine
it may diminish the excretion rate when combined with corifollitropin alfa resulting in an enhanced serum level
spironolactone and hydrochlorothiazide
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
Actions and spectrum:
When benzylpenicilloyl polylysine comes into contact with reagins (penicilloyl skin sensitizing antibodies), it causes instant wheal and flare-ups that could indicate a higher risk of allergic reactions to penicillin therapy in the future.
Frequency not defined
Allergic reaction
Dyspnea
Inflammation of skin at the test site
Angioedema
Erythema
Urticaria
Hypotension
Black Box Warning
Not listed
Contraindication/Caution:
Contraindication:
Hypersensitivity
Pregnancy consideration:
USFDA pregnancy category: C
Lactation:
Data about the excretion of the drug into human milk is not known
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus `in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Pharmacodynamics:
To identify immunoglobulin E antibodies in individuals with a history of penicillin allergy, benylpenicilloyl polylysine—penicilloyl bound to polylysine—is utilized as a skin-testing reagent. It is thought to be the primary determinant of penicillin metabolism. Roughly 97% of patients with a negative skin test will tolerate penicillin if benzylpenicilloyl and penicillin G (as the only source of minor determinants) are used in the skin test.
Pharmacokinetics:
Limited data available
Absorption
Distribution
Metabolism
Elimination and excretion
Half-life:
Administration:
Benzylpenicilloyl polylysine is administered as an injectable solution.
Patient information leaflet
Generic Name: benzylpenicillin polylysine
Why do we use benzylpenicillin polylysine?
Pre-Pen, also known as benzylpenicillinicilloyl polylysine injection solution, is a skin testing antigen reagent used to measure penicillin (benzylpenicillin or penicillin G) sensitization in patients who may be clinically hypersensitive to penicillin.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
